Edgewise Therapeutics, Inc.
EWTX
$11.42
-$0.15-1.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -39.66M | -34.13M | -31.50M | -28.53M | -30.14M |
| Total Depreciation and Amortization | 629.00K | 602.00K | 534.00K | 525.00K | 533.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.14M | 3.64M | 1.67M | 1.72M | 2.98M |
| Change in Net Operating Assets | 6.94M | 2.51M | 3.19M | -2.32M | -201.00K |
| Cash from Operations | -26.96M | -27.37M | -26.10M | -28.60M | -26.83M |
| Capital Expenditure | -274.00K | -520.00K | -221.00K | -297.00K | -161.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.20M | 25.88M | 37.59M | -268.01M | 27.14M |
| Cash from Investing | 20.92M | 25.36M | 37.37M | -268.31M | 26.98M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.90M | 3.55M | 2.00M | 241.07M | 52.94M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -214.00K | -48.00K | -- | 49.00K |
| Cash from Financing | 2.90M | 3.33M | 1.95M | 241.07M | 52.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.14M | 1.32M | 13.22M | -55.83M | 53.14M |
